FGF21 protein
- Known as:
- FGF21 protein
- Catalog number:
- 80R-4397
- Product Quantity:
- 50 ug
- Category:
- -
- Supplier:
- Fitzgerald
- Gene target:
- FGF21 protein
Related genes to: FGF21 protein
- Gene:
- FGF21 NIH gene
- Name:
- fibroblast growth factor 21
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 19q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 1999-11-26
- Date modifiied:
- 2014-11-18
Related products to: FGF21 protein
Related articles to: FGF21 protein
- Although educational attainment influences both cognitive function and metabolic regulation, the biological mechanisms underlying this relationship remain unclear. This study investigated whether cerebrospinal fluid fibroblast growth factor 21 (CSF FGF21) mediates the association between educational attainment and cognitive function, and whether this pathway is moderated by the KLB rs17618244 genotype. - Source: PubMed
Publication date: 2026/09/05
Lin JianxiaSu LidongYang XiaoyuZhao DanyangLuo XingguangHao LeiLiu YanlongWang Fan - Diabetic retinopathy (DR) is a leading cause of preventable visual loss in type 2 diabetes mellitus (T2DM), yet current screening largely detects disease after microvascular damage has occurred. This review synthesizes emerging evidence that three measurable biomarkers - fibroblast growth factor-21 (FGF21), growth differentiation factor-15 (GDF15), and microalbuminuria -capture complementary dimensions of early DR pathobiology. FGF21 reflects hepatometabolic stress and adaptive signaling via the β-Klotho-FGFR1 axis; GDF15 mirrors mitochondrial/integratedstress-response activation with systemic effects through the glial cell-derived neurotrophic factor family receptor-α-like (GFRAL) REarranged during Transfection (RET); and microalbuminuria indicates systemic endothelial dysfunction and increased microvascular permeability. We narratively integrate cross-sectional, cohort, and meta-analytic studies in human T2DM populations (excluding type 1 diabetes and animal experiments) and map these signals onto a unified metabolic-renal-retinal framework. Across studies, higher circulating FGF21 and GDF15 associate with DR presence and severity, while microalbuminuria correlates with DR grade and predicts progression independent of glycemic control. We propose a tri-biomarker model in which chronic lipotoxicity and oxidative stress elevate FGF21/GDF15, drive endothelial injury detectable as microalbuminuria, and together forecast early retinal microangiopathy. Translational implications include risk stratification before funduscopic changes, therapy monitoring for metabolic/mitochondrial targets, and development of multimarker algorithms alongside OCTA imaging. To our knowledge, this is the first review to integrate FGF21, GDF15, and microalbuminuria as a coherent predictive axis for early DR in T2DM, highlighting priorities for longitudinal validation and population-specific cut-offs. - Source: PubMed
Publication date: 2026/07/07
Mustakin - To evaluate the crosstalk between the liver, heart, and kidneys in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), highlighting the distinct regulatory roles of non-traditional hepatokines, and to assess shared therapeutic targets and molecular mechanisms driving cardiorenal complications in MASLD patients. - Source: PubMed
Publication date: 2026/09/04
Taylor Lucy CAdenawoola Michael IWingfield Claire BNadolski Maren KStec David E - /Aims Severe obesity is a major global health challenge and a key driver of hepatic steatosis through systemic insulin resistance and enhanced de novo lipogenesis. Excessive hepatic triglyceride accumulation represents a central metabolic consequence of this condition. This study aimed to identify immune-derived regulators of liver lipid metabolism and to define the mechanistic role of interleukin-13 (IL-13) in obesity-associated liver disease progression. - Source: PubMed
Publication date: 2026/09/03
von Bülow VerenaFelske Dejan ARiebeling Sarah BSchmidt Fabian PStettler FrederikSchmid AndreasKarrasch ThomasEder KlausMost ErikaMorlock GertrudHaase AnnikaBier JensHermanns Heike MGeier AndreasTuffs ChristopherPons-Kühnemann JörnRoderfeld MartinRoeb Elke - The American Association for the Study of Liver Diseases (AASLD) recommends that a decline in liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) can be used as a non-invasive endpoint for treatment response in metabolic dysfunction-associated steatohepatitis (MASH), but there are limited data supporting this statement. We examined the association between a ≥30% relative decline in LSM and fibrosis regression. - Source: PubMed
Publication date: 2026/09/02
Loomba RohitChen RuiqiuWang YouxinBettencourt RickiMadamba EgbertTesfai KalebRichards LisaMuthiah MarkTan EuniceYoung Dan YockGottwald Mildred DFeng ShibaoMargalit MayaHuang Daniel Q